212 related articles for article (PubMed ID: 35513723)
1. CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk.
Baer C; Kimura S; Rana MS; Kleist AB; Flerlage T; Feith DJ; Chockley P; Walter W; Meggendorfer M; Olson TL; Cheon H; Olson KC; Ratan A; Mueller ML; Foran JM; Janke LJ; Qu C; Porter SN; Pruett-Miller SM; Kalathur RC; Haferlach C; Kern W; Paietta E; Thomas PG; Babu MM; Loughran TP; Iacobucci I; Haferlach T; Mullighan CG
Nat Genet; 2022 May; 54(5):637-648. PubMed ID: 35513723
[TBL] [Abstract][Full Text] [Related]
2. CCL22 Mutations Promote NK-cell Lymphoproliferative Disease.
Cancer Discov; 2022 Jul; 12(7):OF17. PubMed ID: 35554510
[TBL] [Abstract][Full Text] [Related]
3. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia.
Jerez A; Clemente MJ; Makishima H; Koskela H; Leblanc F; Peng Ng K; Olson T; Przychodzen B; Afable M; Gomez-Segui I; Guinta K; Durkin L; Hsi ED; McGraw K; Zhang D; Wlodarski MW; Porkka K; Sekeres MA; List A; Mustjoki S; Loughran TP; Maciejewski JP
Blood; 2012 Oct; 120(15):3048-57. PubMed ID: 22859607
[TBL] [Abstract][Full Text] [Related]
4. STAT3 mutations in natural killer cells are associated with cytopenia in patients with chronic lymphoproliferative disorder of natural killer cells.
Kawakami T; Sekiguchi N; Kobayashi J; Yamane T; Nishina S; Sakai H; Hirabayashi Y; Nakazawa H; Ishida F
Int J Hematol; 2019 May; 109(5):563-571. PubMed ID: 30859397
[TBL] [Abstract][Full Text] [Related]
5. A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells.
Gasparini VR; Binatti A; Coppe A; Teramo A; Vicenzetto C; Calabretto G; Barilà G; Barizza A; Giussani E; Facco M; Mustjoki S; Semenzato G; Zambello R; Bortoluzzi S
Blood Cancer J; 2020 Apr; 10(4):42. PubMed ID: 32321919
[TBL] [Abstract][Full Text] [Related]
6. NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment.
Mailloux AW; Young MR
J Immunol; 2009 Mar; 182(5):2753-65. PubMed ID: 19234170
[TBL] [Abstract][Full Text] [Related]
7. The utility of flow cytometry in differentiating NK/T cell lymphoma from indolent and reactive NK cell proliferations.
de Mel S; Li JB; Abid MB; Tang T; Tay HM; Ting WC; Poon LM; Chung TH; Mow B; Tso A; Ong KH; Chng WJ; Liu TC
Cytometry B Clin Cytom; 2018 Jan; 94(1):159-168. PubMed ID: 28431200
[TBL] [Abstract][Full Text] [Related]
8. Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools.
Kurt H; Jorgensen JL; Amin HM; Patel KP; Wang SA; Lin P; Kanagal-Shamanna R; Loghavi S; Thakral B; Khogeer HA; Jabbour EJ; Li S; Yin CC; Medeiros LJ; Khoury JD
Eur J Haematol; 2018 May; 100(5):444-454. PubMed ID: 29385279
[TBL] [Abstract][Full Text] [Related]
9. Linking the KIR phenotype with STAT3 and TET2 mutations to identify chronic lymphoproliferative disorders of NK cells.
Pastoret C; Desmots F; Drillet G; Le Gallou S; Boulland ML; Thannberger A; Doncker AV; Salaun V; Damaj GL; Veyrat-Masson R; Tournilhac O; Moignet A; Pangault C; Roussel M; Fest T; Lamy T
Blood; 2021 Jun; 137(23):3237-3250. PubMed ID: 33512451
[TBL] [Abstract][Full Text] [Related]
10. Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy.
Viney JM; Andrew DP; Phillips RM; Meiser A; Patel P; Lennartz-Walker M; Cousins DJ; Barton NP; Hall DA; Pease JE
J Immunol; 2014 Apr; 192(7):3419-27. PubMed ID: 24563252
[TBL] [Abstract][Full Text] [Related]
11. Natural Killer Cells Generated From Human Induced Pluripotent Stem Cells Mature to CD56
Euchner J; Sprissler J; Cathomen T; Fürst D; Schrezenmeier H; Debatin KM; Schwarz K; Felgentreff K
Front Immunol; 2021; 12():640672. PubMed ID: 34017328
[TBL] [Abstract][Full Text] [Related]
12. CD56
Vujanovic L; Chuckran C; Lin Y; Ding F; Sander CA; Santos PM; Lohr J; Mashadi-Hossein A; Warren S; White A; Huang A; Kirkwood JM; Butterfield LH
Front Immunol; 2019; 10():14. PubMed ID: 30761123
[TBL] [Abstract][Full Text] [Related]
13. Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells.
Faget J; Biota C; Bachelot T; Gobert M; Treilleux I; Goutagny N; Durand I; Léon-Goddard S; Blay JY; Caux C; Ménétrier-Caux C
Cancer Res; 2011 Oct; 71(19):6143-52. PubMed ID: 21852386
[TBL] [Abstract][Full Text] [Related]
14. Participation of the CD94 receptor complex in costimulation of human natural killer cells.
Voss SD; Daley J; Ritz J; Robertson MJ
J Immunol; 1998 Feb; 160(4):1618-26. PubMed ID: 9469418
[TBL] [Abstract][Full Text] [Related]
15. Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309.
Inngjerdingen M; Damaj B; Maghazachi AA
J Immunol; 2000 Apr; 164(8):4048-54. PubMed ID: 10754297
[TBL] [Abstract][Full Text] [Related]
16. Cancer-associated fibroblast-derived interleukin-1β activates protumor C-C motif chemokine ligand 22 signaling in head and neck cancer.
Huang YH; Chang CY; Kuo YZ; Fang WY; Kao HY; Tsai ST; Wu LW
Cancer Sci; 2019 Sep; 110(9):2783-2793. PubMed ID: 31325403
[TBL] [Abstract][Full Text] [Related]
17. The early expansion of anergic NKG2A
Roberto A; Di Vito C; Zaghi E; Mazza EMC; Capucetti A; Calvi M; Tentorio P; Zanon V; Sarina B; Mariotti J; Bramanti S; Tenedini E; Tagliafico E; Bicciato S; Santoro A; Roederer M; Marcenaro E; Castagna L; Lugli E; Mavilio D
Haematologica; 2018 Aug; 103(8):1390-1402. PubMed ID: 29700172
[TBL] [Abstract][Full Text] [Related]
18. Chronic lymphoproliferative disorder of NK cells with TNFAIP3 and DNMT3A mutations.
Bulterys PL; Silva O
Blood; 2021 Jun; 137(24):3460. PubMed ID: 34137843
[No Abstract] [Full Text] [Related]
19. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
[TBL] [Abstract][Full Text] [Related]
20. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis.
Pierson BA; Miller JS
Blood; 1996 Sep; 88(6):2279-87. PubMed ID: 8822949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
